Baxter International Stock Price, News & Analysis (NYSE:BAX)

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.
View BAX analyst ratings or view top-rated stocks.

12 analysts have issued 12 month price targets for Baxter International's stock. Their BAX share price targets range from $36.00 to $56.00. On average, they expect the company's stock price to reach $46.83 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for BAX or view top-rated stocks among Wall Street analysts.

Baxter International's stock was trading at $50.97 on January 1st, 2023. Since then, BAX shares have decreased by 28.3% and is now trading at $36.54.
View the best growth stocks for 2023 here.

Baxter International saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 10,340,000 shares, an increase of 13.6% from the October 31st total of 9,100,000 shares. Based on an average daily volume of 5,040,000 shares, the days-to-cover ratio is currently 2.1 days.
View Baxter International's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our BAX earnings forecast.

Baxter International Inc. (NYSE:BAX) posted its quarterly earnings data on Thursday, November, 2nd. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. The medical instruments supplier earned $3.71 billion during the quarter, compared to the consensus estimate of $3.69 billion. Baxter International had a net margin of 17.34% and a trailing twelve-month return on equity of 21.38%.

Baxter International announced a quarterly dividend on Tuesday, November 14th. Stockholders of record on Friday, December 1st will be given a dividend of $0.29 per share on Tuesday, January 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date of this dividend is Thursday, November 30th.
Read our dividend analysis for BAX.

Baxter International (NYSE:BAX) pays an annual dividend of $1.16 per share and currently has a dividend yield of 3.17%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 22.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BAX will have a dividend payout ratio of 38.28% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BAX.

ETFs with the largest weight of Baxter International (NYSE:BAX) stock in their portfolio include Simplify Health Care ETF (PINK), BTD Capital Fund (DIP), First Trust Indxx Medical Devices ETF (MDEV), iShares U.S. Medical Devices ETF (IHI), BlackRock Large Cap Value ETF (BLCV), Invesco Zacks Mid-Cap ETF (CZA), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and SPDR S&P Health Care Equipment ETF (XHE).

Baxter International updated its fourth quarter earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $0.85-$0.88 for the period, compared to the consensus earnings per share estimate of $0.85. The company issued revenue guidance of $3.93-$3.96 billion, compared to the consensus revenue estimate of $3.83 billion.

506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), Abbott Laboratories (ABT), Procter & Gamble (PG), AT&T (T) and Verizon Communications (VZ).

Baxter International's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ameriprise Financial Inc. (2.14%), Bank of New York Mellon Corp (1.28%), Pzena Investment Management LLC (1.13%), Carmignac Gestion (0.96%), California Public Employees Retirement System (0.62%) and Shapiro Capital Management LLC (0.60%). Insiders that own company stock include Albert P L Stroucken, Andrew Frye, Brian Stevens, Jacqueline Kunzler and Jeanne K Mason.
View institutional ownership trends.

Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.